Plain-English translation of NCT05764057 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether dapagliflozin, a medication already used for diabetes, can help protect your heart after a heart attack. Researchers want to see if this medication, given on top of standard heart attack care, can prevent further weakening of your heart muscle and help it recover better over six months.
After a heart attack, the heart often becomes weaker and scarred, which can lead to long-term heart problems. This trial is trying to find out if this medication can slow down or prevent that damage and help more patients recover better.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the medication or a placebo (a dummy pill) once daily for six months, alongside your regular heart medications. You will have four clinic visits: at the start, at hospital discharge, at three months, and at six months. At the first and final visits, you'll have heart ultrasounds to measure how well your heart is pumping. The research team will also call you during the study to check on how you're doing and make sure you're tolerating the treatment well.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
France